Adalimumab-EU

BIOLOGICAL2 trials

Sponsors

Pfizer, Turgut İlaçları A.Ş.

Conditions

Healthy ParticipantsHealthy Subjects

Phase 1

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

CompletedNCT02237729

PfizerHealthy Subjects

Start: 2014-09-30End: 2015-03-31Updated: 2015-04-13

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

CompletedNCT04439929

Turgut İlaçları A.Ş.Healthy Participants

Start: 2019-07-17End: 2020-01-16Updated: 2020-06-19

Related Papers

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

RMD Open2022-09-011 citations

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

2018-08-1541 citations